Biosimilars Boost In Europe: 2017 Kicks Off With Three Approvals And Backing From ESMO

 
• By Ian Schofield
Reducing costs
Greater use of biosimilars, particularly in cancer, can save on healthcare costs

More from Biosimilars

More from Biosimilars & Generics